Rise in Medical Surgeries Expected to Drive Global Antifibrinolytic Drugs Market: Ken Research REQUEST FOR SAMPLE REPORT Buy Now Request For sample Report × Report Title Name Email Designation Phone No Comapny Name Comapny URL Country -- Please Select Your Country -- Afganistan Africa Albania Algeria Andorra Angola Anguilla Antigua and Barbuda Argentina Armenia Aruba Asia Australasia Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bonaire Bosnia Herzegovina Botswana Brazil BRICS British Virgin Islands Brunei Darussalam Bulgaria Burkina Faso Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Central and South America Chad Chile China Colombia Comoros Congo Costa Rica Cote d'Ivoire Croatia Cuba Curacao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Europe European Union Falkland Islands Faroe Islands Fiji Finland France French Guiana French Polynesia Gabon Gambia Georgia Germany Ghana Gibraltar Global Great Britain Greece Greenland Grenada Guadeloupe Guam Guatemala Guerney & Alderney Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Ivory Coast Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo Kuwait Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Man (Island of) Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Micronesia Middle East Minnesota Moldova Monaco Mongolia Monserrat Montenegro Morocco Morroco Mozambique Myanmar Namibia Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue North America North Korea Norway Oman Pakistan Palau Palestine Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Qatar Reunion Romania Russia Rwanda Saint Helena Saint Lucia Saint Martin Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa Samoa (American) San Marino Sao Tome and Principe Saudi Arabia Scandinavia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten Slovakia Slovenia Solomon (Islands) Somalia South Africa South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Islands Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand Timor Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Vatican City Venezuela Vietnam Virgin Islands Western Sahara Yemen Zambia Zimbabwe Requirement Submit Antifibrinolytic drugs are also known as fibrinolytic inhibitors. They are primarily used for preventing the fibrinolysis or lysis of blood clots. The fibrinolysis is basically a process which is stimulated plasminogen used for removing the excess fibrin. Moreover, they are used for controlling the massive hemorrhage and for other coagulation disorders. The hemophilia, antifibrinolytic agents consisting of tranexamic acid or epsilon aminocaproic acid are generally used for oral bleeding or the dental surgery. Some of the most common antifibrinolytic drugs such as tranexamic acid and ε-aminocaproic acid, and the serine protease inhibitor, aprotinin and others. According to study, “Antifibrinolytic Drugs Market by Indication (Gynecology, Hereditary Angiedema, Fibrinolytic Response Testing, Surgeries, and Others) and End user (Hospitals & Clinics, Ambulatory Surgical Centers, and Healthcare Specialty Process): Global Opportunity Analysis and Industry Forecast, 2019-2026”. Some of the key companies that are currently working in the global Antifibrinolytic drugs market are Acic Fine Chems, Aurobindo Pharma Ltd., Zydus Cadila, Xanodyne Pharmaceuticals, Akorn, Mylan, Pfizer (GenMed), Amerigen Pharms Ltd, Sanofi, and Takeda. Based on indications, antifibrinolytic drugs market is segmented into gynecology, fibrinolytic response testing, hereditary angiedema, surgeries, and others. Gynecology includes menorrhagia, gynecological surgery, pregnancy, haemorrhage, parturition, bleeding disorders, Gastrointestinal (GI) bleeding and dental surgery. Gynecology segment holds major share in market and is expected to exhibit a prominent growth rate in the near future, due to rise in adoption of these drugs to prevent menorrhagia i.e. heavy menstrual flow. Surgeries include cardiac surgery, liver surgery, orthopedic surgery and neurosurgery. Based on drug type, market is segmented into Amicar, Tranexamic acid injection, Aminocaproic acid, Tranexamic acid oral, Aprotinin, RiaSTAP, Cyklokapron, Trasylol and Lysteda. In addition, based on end-user, market is segmented into hospitals, healthcare specialty processes, ambulatory surgical centers, clinics and others. Hospital segment dominates the market owing to increase in usage of these drugs in hospitals as most of the surgeries such as neurosurgeries and cardiovascular are performed in hospitals. The antifibrinolytic drugs market is driven by significant increase in surgical procedures, followed by surge in severe road accidents, growth in high-risk geriatric population, surge in incidence of angioedema and growth in healthcare investments. However, high cost of these drugs may impact the market. Moreover, increase in research & development (R&D) for developing novel innovative antifibrinolytic drugs is a key opportunity for market. Based on geography, the North-American is the dominating region in the antifibrinolytic drugs market owing to broad technical applications of antifibrinolytic drugs, increase in strict rules at the work place and rise in awareness about these drugs in the region. Whereas, the European and Asian-Pacific regions are estimated to witness higher growth rate due to high disposable income, mandatory medical insurance and high research & development in the health care sector over the forecast period. In upcoming years, it is estimated that future of the market will be bright as a result of considerable surge in prevalence of bleeding disorders during the forecast period. The global antifibrinolytic drugs market was valued at US $13,593 million in 2018 and is anticipated to reach US $19,333 million by 2026, registering a CAGR of 4.5% from 2019-2026. For More Information, Click on the Link Below:- Global Antifibrinolytic Drugs Market Contact Us:- Ken Research Ankur Gupta, Head Marketing & Communications Ankur@kenresearch.com +91-9015378249 Tags: Acic Fine Chems Antifibrinolytic Drugs Market Share, Antifibrinolytic Drugs Market, Aurobindo Pharma Ltd. Antifibrinolytic Drugs Market Share, China Antifibrinolytic Drugs Market, Europe Antifibrinolytic Drugs Market, Global Antifibrinolytic Drugs Industry, Global Antifibrinolytic Drugs Industry Research Report, Global Antifibrinolytic Drugs Market, Global Antifibrinolytic Drugs Market Analysis, Global Antifibrinolytic Drugs Market Competition Analysis, Global Antifibrinolytic Drugs Market Competitive Landscape, Global Antifibrinolytic Drugs Market Drivers, Global Antifibrinolytic Drugs Market Dynamics, Global Antifibrinolytic Drugs Market Forecast, Global Antifibrinolytic Drugs Market Insight, Global Antifibrinolytic Drugs Market Opportunity, Global Antifibrinolytic Drugs Market Outlook, Global Antifibrinolytic Drugs Market Overview, Global Antifibrinolytic Drugs Market Research Report, Global Antifibrinolytic Drugs Market Share, Global Antifibrinolytic Drugs Market Trends, India Antifibrinolytic Drugs Market, Japan Antifibrinolytic Drugs Market, US Antifibrinolytic Drugs Market, Xanodyne Pharmaceuticals Antifibrinolytic Drugs Market Revenue